{"id":19791,"date":"2021-06-29T16:19:43","date_gmt":"2021-06-29T14:19:43","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=19791"},"modified":"2021-06-29T16:19:44","modified_gmt":"2021-06-29T14:19:44","slug":"probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/","title":{"rendered":"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.probiogen.de\" target=\"_blank\" rel=\"noreferrer noopener\">ProBioGen<\/a> and <a href=\"http:\/\/www.lavatherapeutics.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">LAVA Therapeutics N.V.<\/a> announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA&#8217;s pipeline.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Under the agreement and using its <a href=\"https:\/\/www.probiogen.de\/gmp-production-cell-lines.html\" target=\"_blank\" rel=\"noreferrer noopener\">CHO.RiGHT<\/a>\u00ae expression platform, including its <a href=\"https:\/\/www.probiogen.de\/directedluck-transposase-with-epigenetic-targeting.html\" target=\"_blank\" rel=\"noreferrer noopener\">DirectedLuck<\/a>\u2122 Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line development of a novel gamma-delta bsTCE.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;We are delighted to continue our collaboration with LAVA to develop cell lines for another novel gamma-delta bsTCE. Our proven cell line development platform, which also includes our Transposase technology, is perfectly suited for novel protein formats&#8221;, <strong>said ProBioGen&#8217;s Chief Executive Officer Dr. Lutz Hilbrich.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;Based on the great results from our previous agreement, we would look forward working with ProBioGen again&#8221;, <strong>commented Stephen Hurly, Chief Executive Officer and President of LAVA Therapeutics.<\/strong> &#8220;ProBioGen exceeded our expectations and proved to be a scientifically driven partner with a proven development platform and a dedicated analytical panel for bispecific antibody formats.&#8221;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source: LAVA Therapeutics (<a href=\"https:\/\/www.b3cnewswire.com\/202106222243\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific.html\">Press release<\/a>)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA&#8217;s pipeline. Under the agreement and using its CHO.RiGHT\u00ae expression platform, including its DirectedLuck\u2122 Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-19791","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific - hollandbio\" \/>\n<meta property=\"og:description\" content=\"ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA&#8217;s pipeline. Under the agreement and using its CHO.RiGHT\u00ae expression platform, including its DirectedLuck\u2122 Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T14:19:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-06-29T14:19:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"HollandBIO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"HollandBIO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/\"},\"author\":{\"name\":\"HollandBIO\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\"},\"headline\":\"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific\",\"datePublished\":\"2021-06-29T14:19:43+00:00\",\"dateModified\":\"2021-06-29T14:19:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/\"},\"wordCount\":187,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/\",\"name\":\"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2021-06-29T14:19:43+00:00\",\"dateModified\":\"2021-06-29T14:19:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\",\"name\":\"HollandBIO\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/","og_locale":"en_US","og_type":"article","og_title":"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific - hollandbio","og_description":"ProBioGen and LAVA Therapeutics N.V. announced the closing of a second cell line development agreement to support a bispecific gamma-delta T cell engager (TCE) candidate in LAVA&#8217;s pipeline. Under the agreement and using its CHO.RiGHT\u00ae expression platform, including its DirectedLuck\u2122 Transposase technology for the generation of stable high-titer cell lines, ProBioGen will conduct cell line [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/","og_site_name":"hollandbio","article_published_time":"2021-06-29T14:19:43+00:00","article_modified_time":"2021-06-29T14:19:44+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"HollandBIO","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"HollandBIO","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/"},"author":{"name":"HollandBIO","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea"},"headline":"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific","datePublished":"2021-06-29T14:19:43+00:00","dateModified":"2021-06-29T14:19:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/"},"wordCount":187,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/","name":"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2021-06-29T14:19:43+00:00","dateModified":"2021-06-29T14:19:44+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/probiogen-and-lava-therapeutics-n-v-sign-agreement-for-cell-line-development-for-manufacturing-of-a-novel-bispecific\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"ProBioGen and LAVA Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea","name":"HollandBIO"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/19791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=19791"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/19791\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=19791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=19791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=19791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}